Peptide CDMO for Process Development: Choose by Stage

A program that needs route or process development should hire an integrated peptide CDMO that can develop the route, analytics, GMP manufacture, and transfer path. A program with a locked process and transfer package should hire a GMP manufacturer, while a program still testing sequences needs a discovery lab.

Use this table before inviting proposals. Choose the row for your next decision, then use its question in every RFP.

The table turns “find a peptide CDMO” into a defined scope of work. A supplier can only quote comparable work when every bidder answers the same stage-specific question.

1. Which CDMO Fits Your Development Stage?

A peptide CDMO selection starts with the next irreversible decision, not with the largest manufacturing network.

Choose a discovery lab when the sequence, modification, salt form, or purity target can still change. The useful output is material and decision records that identify the lead worth developing.

Choose an integrated peptide CDMO when the program needs a repeatable synthesis route, purification approach, impurity-control strategy, analytical methods, and a route into GMP manufacture. ICH Q11 defines process development’s goal as a commercial process that consistently produces drug substance of intended quality.

Choose a GMP manufacturer when your team can hand over a mature process and an analytical package that the receiving site can reproduce. The manufacturing label alone does not prove that the site can solve unresolved route or impurity problems.

For a clinical-to-commercial handoff, use our clinical peptide CDMO guide alongside the decision table.

2. What Must Process Development Deliver Before GMP Manufacture?

Process development should leave the buyer with a package that a GMP team can execute, investigate, and transfer.

Ask for these five outputs:

1. A process map: each synthesis, cleavage, purification, isolation, drying, and packaging step.

2. A quality map: critical quality attributes, or CQAs, are the properties that must remain within limits for the intended product.

3. An impurity plan: likely peptide-related and non-peptide impurities, their sources, and the controls used to manage them.

4. A parameter report: proposed operating ranges, in-process tests, acceptance criteria, expected yields, and hold-time assumptions.

5. A transfer package: batch records, equipment fit, materials, analytical methods, and decisions that need sponsor approval.

For synthetic peptides, the EMA peptide guideline treats purity as a key CQA. It separates peptide-related impurities from reagents, residual solvents, elemental impurities, and other non-peptide impurities.

FDA Q7 also expects master instructions to identify materials, equipment, parameter ranges, sampling, in-process controls, expected yields, and storage instructions. Ask the development team which of those elements exist now and which belong in its proposed scope.

3. Do You Need a Development Lab, a GMP Manufacturer, or Both?

You need both when the scientific work and GMP supply must connect without losing process knowledge.

A development lab fits when your team needs route screening, coupling-condition work, purification development, or early analytical methods. That lab should provide a documented package, not only material.

A GMP manufacturer fits when the route, process controls, specifications, and methods are already mature enough to execute at the receiving site. The manufacturer needs a clear transfer plan before its first campaign.

An integrated CDMO fits when the program needs both jobs under one technical plan. The buyer should still identify the actual development site, GMP site, testing laboratory, and any subcontracted activities.

FDA Q7 requires written quality responsibilities for contract manufacturing and laboratories. It also requires prior evaluation and approval before a contractor passes work to a third party. Put every subcontracted synthesis, testing, packaging, and release activity in the RFP.

4. Which Analytical Package Should a Peptide Program Require?

Require a written test-method matrix that links each quality attribute to its method, status, acceptance criteria, and owner.

Start with identity, assay or content, purity and related substances. Then add product-specific tests for attributes such as counterion, residual solvents, water, particle size, microbial controls, or endotoxin when the molecule and dosage form require them.

Ask the CDMO to label every method as exploratory, fit-for-purpose, transfer-ready, or validated. A fit-for-purpose method supports a current development decision. A validated method has evidence that it performs for its intended use.

ICH Q2(R2) states that validation demonstrates a method’s suitability for its intended purpose. The guideline also says method transfer may require comparative testing or partial or full revalidation.

Stability belongs in the same matrix. ICH Q1A(R2) explains that stress testing can identify degradation products and help establish stability-indicating methods. A stability-indicating method can detect meaningful change during storage.

Purity and content answer different questions. Our peptide HPLC purity and content guide helps procurement and quality teams ask for both results clearly.

5. How Do You Assess Scale-Up and Technology Transfer?

Scale-up readiness means the receiving site can reproduce the agreed process with controlled quality. It does not mean a supplier owns larger equipment.

Use these five checks during technical review:

1. Name the receiving site. Identify the legal entity and location for synthesis, purification, drying, testing, packaging, and release.

2. Map the equipment. Compare reactor, synthesizer, purification, and drying capability with the proposed process.

3. Use representative material. Transfer work should use samples and process conditions that represent the intended manufacture.

4. Set comparability criteria first. Define what process, analytical, impurity, and release results must match before the transfer starts.

5. Assign change-control ownership. State who approves process changes, method changes, deviations, and out-of-specification investigations.

ICH Q11 links process understanding to a control strategy for the drug substance. ICH Q2(R2) specifically addresses analytical transfer between laboratories. Both make transfer planning a development activity, not a shipping task.

For commercial supply, add raw-material strategy, forecast cadence, release timing, packaging, storage, and shipment conditions. Our peptide API supply-chain checklist covers the procurement evidence that should sit beside the technical package.

6. What Should You Ask in a Peptide CDMO RFP?

Send a single RFP that forces every supplier to scope the same work.

Please propose a development plan for our synthetic peptide API. We will provide the sequence, length, modifications, known impurity issues, and prior batch information under a confidentiality agreement.

Our next decision is process development before clinical GMP manufacture. State the proposed synthesis and purification route, development experiments, batch scale path, analytical methods, impurity-control plan, stability work, GMP activities, documentation, transfer plan, and target manufacturing site.

Identify every subcontracted activity. State the proposed acceptance criteria, development reports, batch records, method status, deviation responsibilities, change-control process, assumptions, exclusions, and dependencies.

Include the target market, intended dosage form, required quantity, delivery date, packaging, storage conditions, and expected future demand in the proposal.

Ask whether the supplier can support confidential CMC information through a Type II Drug Master File, or DMF, when that structure fits your filing strategy. An FDA Type II DMF can cover drug substance information, but it is voluntary and reviewed only with a referenced application.

For European programs, an Active Substance Master File can protect the manufacturer’s confidential know-how while leaving the applicant responsible for active-substance quality.

FAQs

Is a Type II DMF Required Before an IND?

No. FDA states that DMFs are not required by law or regulation. A DMF can allow a sponsor to reference confidential manufacturing information without receiving the full file. The sponsor still needs an adequate application and a suitable API package.

How Many Batches Are Needed for a Registration Stability Package?

ICH Q1A(R2) calls for formal stability data on at least 3 primary drug-substance batches for a new drug substance registration package. Those batches should be at least pilot scale and use the same synthetic route as the intended production process. The clinical-stage CMC package should be scoped to the applicable market and trial.

Should We Share the Peptide Sequence Before Selecting a CDMO?

Share enough non-confidential information to assess scope first, then provide the sequence and detailed history under a confidentiality agreement. The initial discussion should still identify sequence length, modifications, intended quantity, dosage form, target market, and major technical risks. That information lets the CDMO propose the correct development path.

At Aarise Pharma, we support pharmaceutical procurement and formulation programs with defined peptide API requirements. Our published peptide API manufacturing scope includes process development and optimization, R&D-to-commercial scale-up, specification review, and batch documentation. Start with the molecule, grade, quantity, and destination market.